



# The Role of Potassium Monitoring in Respiratory Diseases: Clinical Implications of Dyskalemia

Dr. Mohankumar Thekkinkattil \*

**\*Correspondence to:** Dr. Mohankumar Thekkinkattil, Senior Consultant in Pulmonology, Critical care & Sleep Medicine, OneCare Medical Center, Saibaba Colony, Coimbatore 641046, India.

## Copyright

© 2024 **Dr. Mohankumar Thekkinkattil**. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received: 19 Aug 2024

Published: 01 Sep 2024

### **Abstract**

*Potassium homeostasis is crucial in maintaining respiratory function, particularly in patients with underlying respiratory diseases. Imbalances in potassium levels can lead to significant clinical consequences, with both hypokalaemia and hyperkalaemia having distinct impacts. Hypokalaemia, characterized by low serum potassium levels, can exacerbate respiratory muscle weakness, impair the respiratory drive, and increase the risk of respiratory failure. Conversely, hyperkalaemia, marked by elevated serum potassium, may cause cardiac arrhythmias and worsen outcomes in respiratory patients. Proper monitoring and management of potassium levels are essential in respiratory disease management. Key recommendations include regular serum potassium assessments, careful consideration of medications that may alter potassium levels, and prompt correction of any detected imbalances to mitigate complications.*

*Keywords: Potassium homeostasis, respiratory diseases, hypokalaemia, hyperkalaemia, respiratory failure, clinical management.*

### **Introduction**

Potassium is an essential electrolyte that plays a pivotal role in various physiological processes, particularly in muscle and nerve function. It is crucial for maintaining cellular membrane potential, transmitting nerve impulses, and facilitating muscle contraction, including that of the respiratory muscles. Potassium homeostasis is vital for sustaining normal respiratory function, as it directly influences the contractility and endurance of respiratory muscles such as the diaphragm. Disruptions in potassium levels, whether in the form of hypokalemia or hyperkalemia, can have significant clinical implications, especially in patients with preexisting respiratory conditions.

Maintaining a proper potassium balance is essential for optimal respiratory function. Potassium imbalances, or dyskalemias, can lead to severe complications, including respiratory muscle weakness, impaired neural transmission, and increased susceptibility to respiratory failure. Understanding the impact of potassium on respiratory function is crucial for healthcare providers managing patients with respiratory diseases. (1)

The objective of this article is to explore the necessity of monitoring potassium levels in patients with respiratory diseases and to discuss the clinical implications of Dyskalemia. The article will cover the physiological role of potassium in respiratory function, the effects of hypokalemia and hyperkalemia on respiratory muscles, and provide recommendations for the management of potassium imbalances in these patients.

## 1. The Physiology of Potassium and Respiratory Function

### A. Potassium Homeostasis:

Potassium regulation in the body is a complex process involving renal, gastrointestinal, and cellular mechanisms. The kidneys play a primary role in maintaining potassium balance by adjusting the amount of potassium excreted in the urine. Gastrointestinal absorption and cellular uptake also contribute to overall potassium homeostasis [1]. Within cells, potassium is critical for maintaining the resting membrane potential, which is necessary for normal neural transmission and muscle contraction [2]. In the context of respiratory function, potassium is particularly important for the proper functioning of respiratory muscles, including the diaphragm, which is the primary muscle involved in breathing [3].

### B. Impact on Respiratory Muscles:

The strength and endurance of respiratory muscles are directly influenced by potassium levels. Hypokalemia can lead to decreased muscle strength, which may compromise the effectiveness of breathing and lead to respiratory insufficiency [4]. Conversely, hyperkalemia can cause muscle weakness and potentially life-threatening cardiac arrhythmias, which can further exacerbate respiratory problems [5]. Understanding how potassium levels affect respiratory muscles is crucial for preventing complications in patients with respiratory diseases [6].

## 2. Hypokalemia in Respiratory Diseases

### Causes of Hypokalemia in Respiratory Patients:

Several factors can lead to hypokalemia in patients with respiratory diseases. The use of certain medications, such as diuretics, bronchodilators (especially  $\beta_2$ -agonists), and corticosteroids, can cause a significant reduction in serum potassium levels [7]. Additionally, respiratory alkalosis, often seen in patients with hyperventilation, can cause transcellular shifts of potassium from the extracellular to the intracellular space, further lowering serum potassium levels [8]. These mechanisms highlight the importance of regular

potassium monitoring in patients with respiratory conditions to prevent the onset of hypokalemia and its associated complications.

#### A. How Hypokalemia Exacerbates Respiratory Failure

Hypokalemia can significantly worsen respiratory failure by weakening the respiratory muscles, making it difficult for patients to maintain effective ventilation. This condition may lead to hypoventilation, hypercapnia, and an overall decrease in respiratory function. In the context of COPD and asthma, where respiratory muscle strength is already compromised, hypokalemia can further impair the ability to clear secretions and maintain airway patency, increasing the risk of acute respiratory failure [8].

#### B. Case Studies and Recent Research

Recent studies have shown a clear link between hypokalemia and poor outcomes in patients with COPD and asthma. For instance, research has indicated that patients with COPD who develop hypokalemia have a higher risk of hospitalization and mortality. A study by Brown et al. [9] demonstrated that hypokalemia induced by  $\beta_2$ -agonists in asthma patients can lead to significant respiratory complications. Additionally, there are case studies where the correction of hypokalemia has led to significant improvements in respiratory function, demonstrating the critical importance of maintaining normal potassium levels in these patients [10].

### 3. Hyperkalemia in Respiratory Diseases

#### A. Causes of Hyperkalemia in Respiratory Patients

Hyperkalemia, defined as a serum potassium level above 5.0 mEq/L, can occur in respiratory patients due to several factors. Renal insufficiency is a common cause, as the kidneys are unable to excrete excess potassium effectively. The use of potassium-sparing diuretics, often prescribed to manage fluid retention in patients with respiratory diseases, can also contribute to elevated potassium levels. Respiratory acidosis, a common finding in chronic respiratory failure, can lead to intracellular potassium release, exacerbating hyperkalemia. Furthermore, hypercapnia, which is elevated levels of carbon dioxide in the blood, can influence potassium homeostasis, particularly in chronic respiratory failure [11].

#### B. Clinical Manifestations

The clinical manifestations of hyperkalemia include cardiac arrhythmias, muscle weakness, and, in severe cases, respiratory arrest. Cardiac complications are particularly concerning, as hyperkalemia can lead to life-threatening arrhythmias, which may precipitate acute exacerbations of COPD and asthma. Muscle weakness

associated with hyperkalemia can also affect respiratory muscles, further impairing respiratory function and potentially leading to respiratory arrest if left untreated [12].

### C. Case Studies and Recent Research

Studies have highlighted the relationship between hyperkalemia and acute respiratory failure. For example, research has shown that patients with chronic respiratory diseases who develop hyperkalemia have an increased risk of acute respiratory decompensation. Weiner and Wingo [13] reported that hyperkalemia is a significant risk factor for acute exacerbations in COPD patients, particularly those with concurrent renal insufficiency. Additionally, case reports have documented the successful management of hyperkalemia in patients with co-existing renal and respiratory diseases, emphasizing the importance of careful potassium monitoring and management in these populations [14].

## 4. The Role of Potassium Monitoring in Respiratory Care

Maintaining potassium homeostasis is critical in managing patients with respiratory diseases. Regular monitoring of serum potassium levels is essential, especially in patients at risk of dyskalemia, such as those with chronic respiratory failure, renal insufficiency, or those on medications that affect potassium balance. Early detection and correction of both hypokalemia and hyperkalemia can prevent complications and improve clinical outcomes. It is recommended that healthcare providers regularly assess potassium levels in respiratory patients and adjust treatment plans accordingly to maintain optimal potassium balance [15]. Potassium plays a crucial role in maintaining respiratory function, and imbalances in potassium levels can have serious clinical consequences for patients with respiratory diseases. Hypokalemia and hyperkalemia both pose significant risks, including exacerbation of respiratory failure and increased mortality. Regular monitoring and management of potassium levels are essential in preventing these complications and ensuring better outcomes for patients with respiratory conditions.

### Current Guidelines on Potassium Monitoring in Respiratory Patients

Potassium monitoring is an integral part of managing patients with respiratory diseases, especially those on chronic medications that may influence electrolyte balance. Hypokalemia and hyperkalemia are both significant concerns in these patients, as they can exacerbate respiratory symptoms and lead to severe

complications, including respiratory failure and cardiac arrhythmias. Current clinical guidelines highlight the necessity of regular potassium monitoring in these patients.

The American Thoracic Society (ATS) and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommend routine monitoring of serum electrolytes, including potassium, in patients with chronic obstructive pulmonary disease (COPD), particularly during acute exacerbations or when medications that affect potassium balance are initiated or adjusted [16]. These guidelines emphasize that patients receiving  $\beta$ 2-agonists, corticosteroids, or diuretics should have their potassium levels closely monitored due to the risk of dyskalemia associated with these drugs [17]. The European Respiratory Society (ERS) also advises regular potassium monitoring in patients with chronic respiratory failure, particularly those on long-term oxygen therapy or mechanical ventilation, as these conditions can exacerbate electrolyte imbalances [18].

### **Role of Regular Electrolyte Monitoring in Preventing Complications Related to Dyskalemia**

Regular monitoring of electrolyte levels, particularly potassium, is crucial in preventing complications associated with dyskalemia in respiratory patients. Potassium is vital for the proper functioning of respiratory muscles, and imbalances can significantly impair these muscles, leading to respiratory distress or failure. Maintaining potassium within the normal range is critical for preventing the development of arrhythmias, which can further complicate the respiratory status of these patients [19].

Research has consistently shown that regular monitoring of potassium levels can reduce the incidence of severe hypokalemia and hyperkalemia, thus preventing hospitalizations and improving overall outcomes. A study by Wright et al. demonstrated that regular electrolyte checks in COPD patients significantly reduced the risk of acute exacerbations and the associated complications [20]. Furthermore, consistent monitoring allows for early detection and timely correction of potassium imbalances, which is vital in preventing life-threatening events such as respiratory arrest in patients with chronic respiratory diseases [21].

### **Diagnostic Tools and Frequency of Monitoring and methods for monitoring Potassium Levels**

Several diagnostic tools are available for monitoring potassium levels in respiratory patients:

1. Serum Potassium Tests: The most widely used method for assessing potassium levels is the serum potassium test. This test provides a direct measurement of extracellular potassium concentration, offering valuable information about the patient's electrolyte status [22].
2. ECG Monitoring: Electrocardiography (ECG) is another important tool for detecting dyskalemia, particularly its cardiac effects. Characteristic ECG changes, such as peaked T waves in hyperkalemia or

flattened T waves in hypokalemia, can indicate significant potassium imbalances even before serum levels show abnormalities [23].

3. Point-of-Care Testing: Point-of-care testing devices enable rapid assessment of potassium levels at the bedside, making them particularly useful in acute settings such as emergency rooms and intensive care units (ICUs) [24]. These devices can provide immediate results, allowing for prompt intervention in cases of severe dyskalemia.

### **Recommendations for Frequency of Potassium Checks**

The frequency of potassium checks should be tailored to the patient's clinical status, underlying respiratory condition, and risk factors for dyskalemia:

1. During Exacerbations: For patients experiencing an exacerbation of COPD or asthma, it is recommended to monitor potassium levels at least once daily until the patient stabilizes. This is especially important for patients receiving medications such as  $\beta$ 2-agonists or corticosteroids, which can significantly alter potassium balance [25].

2. In ICU Settings: Critically ill patients in the ICU, particularly those on mechanical ventilation or intravenous medications affecting potassium levels, may require more frequent monitoring. In such cases, potassium levels should be checked every 4-6 hours to allow for the prompt detection and correction of any imbalances [26].

3. Stable Outpatients: In stable outpatients with chronic respiratory conditions, potassium levels should be monitored regularly during routine follow-up visits, typically every 3-6 months. This frequency may vary depending on the patient's medication regimen, overall health status, and any recent changes in their treatment plan [27].

Maintaining potassium homeostasis is crucial in the management of respiratory diseases. Adhering to current guidelines for potassium monitoring can prevent complications related to dyskalemia and improve patient outcomes. Regular monitoring, particularly in high-risk patients, allows for early detection and timely intervention, reducing the risk of severe respiratory and cardiac events. By integrating serum potassium testing, ECG monitoring, and point-of-care tools into routine clinical practice, healthcare providers can ensure optimal care for patients with respiratory diseases.

## **Approaches to Correcting Hypokalemia and Hyperkalemia in Respiratory Patients:**

### **Tailoring Treatment Based on Individual Patient Risk Factors and Underlying Conditions:**

Effective management of potassium imbalances in respiratory patients requires a tailored approach that considers individual risk factors and underlying conditions. The treatment for hypokalemia and hyperkalemia must be adjusted based on the patient's overall health status, comorbidities, and specific respiratory condition.

**A. Correcting Hypokalemia:** Hypokalemia, characterized by low potassium levels, can be addressed through several strategies:

1. **Oral Potassium Supplements:** For mild cases of hypokalemia, oral potassium supplements are often sufficient. Potassium chloride is commonly used, though other formulations may be preferred based on patient tolerance and compliance [28].
2. **Intravenous Potassium:** In more severe cases, especially when rapid correction is needed, intravenous potassium chloride may be administered. Care must be taken to avoid overcorrection, which can lead to hyperkalemia [29].
3. **Addressing Underlying Causes:** Identifying and treating the underlying cause of hypokalemia, such as adjusting medications (e.g., discontinuing or reducing the dose of diuretics) or addressing metabolic alkalosis, is crucial [30].

**B. Correcting Hyperkalemia:** Hyperkalemia, or elevated potassium levels, requires a more nuanced approach:

1. **Calcium Gluconate:** Calcium gluconate can be used to stabilize cardiac membranes and reduce the risk of arrhythmias in acute hyperkalemia [31].
2. **Insulin and Glucose:** Insulin promotes cellular uptake of potassium, thereby lowering serum potassium levels. This is often administered along with glucose to prevent hypoglycemia [32].
3. **Diuretics and Dialysis:** For chronic hyperkalemia, especially in patients with renal insufficiency, diuretics may help increase potassium excretion. In severe cases, dialysis might be necessary to remove excess potassium from the body [33].
4. **Addressing Contributing Factors:** Managing underlying conditions, such as controlling renal dysfunction or modifying medications that contribute to hyperkalemia, is essential for long-term management [34].

### **C. Clinical Implications and Case Management & Impact on Treatment Outcomes**

Maintaining optimal potassium levels is crucial for improving respiratory outcomes. Both hypokalemia and hyperkalemia can significantly impact respiratory function, exacerbating symptoms and potentially leading to severe complications. For instance, hypokalemia can impair respiratory muscle strength, leading to respiratory failure, while hyperkalemia can cause life-threatening cardiac arrhythmias that complicate respiratory management [35,36].

### **D. The Role of Interdisciplinary Care**

Effective management of potassium imbalances often requires an interdisciplinary approach. Pulmonologists, nephrologists, and intensivists must collaborate to address the complex interplay between respiratory conditions and electrolyte imbalances. This team-based approach ensures comprehensive care, addressing both the respiratory and metabolic aspects of patient health [37,38].

### **Future Directions and Research Needs and Gaps in Current Research**

Despite advances in understanding potassium regulation, several gaps remain in the research. For example, there is a need for more studies exploring the long-term impact of potassium imbalances on respiratory diseases and the effectiveness of various correction strategies in different patient populations [39]. Additionally, research into the optimal frequency and methods for monitoring potassium levels in patients with chronic respiratory diseases is limited.

### **Potential for New Therapeutic Strategies**

Future research should focus on developing new therapeutic strategies that target potassium balance more effectively. Innovations could include novel pharmacological agents that better manage potassium levels without adverse effects or improved monitoring technologies that provide more accurate and real-time data [40]. Such advancements could enhance patient outcomes and reduce the incidence of severe complications related to dyskalemia.(41)

Maintaining potassium homeostasis is vital in managing respiratory diseases. Optimal potassium levels are crucial for preventing complications and improving overall treatment outcomes. Regular monitoring and tailored treatment strategies based on individual risk factors and underlying conditions are essential. An interdisciplinary approach involving pulmonologists, nephrologists, and intensivists is necessary for effective management of potassium imbalances.

Further research is needed to address current gaps in knowledge and to develop new therapeutic strategies. As the field evolves, there is a strong call to action for continued research and guideline development to enhance the care of patients with respiratory diseases and potassium imbalances

## **Hypokalemia and Hyperkalemia in Respiratory Diseases**

### **A. Hypokalemia and Respiratory Diseases**

Hypokalemia, characterized by low potassium levels, has been linked to adverse outcomes in various respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma. Recent clinical trials and observational studies have underscored the impact of hypokalemia on respiratory function and management. In COPD patients, hypokalemia has been associated with increased morbidity and mortality. For instance, a study by Yang et al. (2021) found that hypokalemia in COPD patients significantly worsened their condition, leading to increased hospitalizations and longer recovery times [42]. Another observational study highlighted that low potassium levels were correlated with more severe exacerbations and poorer overall outcomes in COPD patients [43]. These findings emphasize the need for vigilant monitoring of potassium levels in COPD management. In asthma, hypokalemia can exacerbate symptoms and complicate treatment. Research by Peters et al. (2022) showed that hypokalemia, often a side effect of  $\beta$ 2-agonist therapy, can lead to increased airway hyperreactivity and worsening of asthma control [44]. The study concluded that managing potassium levels is crucial for optimizing asthma treatment and preventing severe exacerbations. Guidelines for managing hypokalemia in critical care settings emphasize the importance of prompt and effective correction of potassium imbalances. The American College of Critical Care Medicine (ACCM) recommends frequent monitoring of potassium levels in critically ill patients and rapid intervention with oral or intravenous potassium supplements based on severity [45]. They stress the need for individualized treatment plans to address the underlying causes of hypokalemia, such as medication side effects or metabolic disturbances [46].

### **B. Hyperkalemia and Respiratory Diseases**

Hyperkalemia, or elevated potassium levels, poses significant risks to patients with chronic respiratory diseases. Studies exploring the incidence and outcomes of hyperkalemia in these patients reveal a complex interplay between potassium levels, renal function, and respiratory health. In chronic respiratory diseases, hyperkalemia is often linked to renal impairment. A study by Singh et al. (2020) demonstrated that

hyperkalemia frequently occurs in patients with chronic kidney disease and COPD, leading to worsened respiratory outcomes and increased risk of cardiovascular events [47]. The study highlights the need for close monitoring of potassium levels in this patient population to prevent severe complications. The relationship between renal failure, hyperkalemia, and respiratory function is particularly concerning. Research by Hsu et al. (2019) found that patients with chronic renal failure who developed hyperkalemia experienced significant respiratory distress, partly due to the combined effects of potassium imbalance and compromised renal function [48]. The study suggests that managing hyperkalemia in these patients requires a multidisciplinary approach involving nephrologists and pulmonologists to address both renal and respiratory issues.

## Conclusion

Maintaining potassium homeostasis is crucial for optimizing respiratory health and managing respiratory diseases. Both hypokalemia and hyperkalemia have profound impacts on respiratory function, influencing both the severity of respiratory conditions and the efficacy of treatment.

Hypokalemia has been shown to exacerbate respiratory symptoms and complications in conditions such as chronic obstructive pulmonary disease (COPD) and asthma. Clinical studies highlight the association between low potassium levels and worsened respiratory outcomes, including increased hospitalizations and prolonged recovery periods [49,50,51]. Current guidelines emphasize the importance of regular potassium monitoring and timely correction to prevent these adverse effects [52,53]. In critical care settings, prompt intervention with oral or intravenous potassium supplements is essential to manage hypokalemia effectively and mitigate its impact on respiratory function [54].

Hyperkalemia, on the other hand, poses significant risks, particularly in patients with chronic respiratory diseases and renal impairment. Elevated potassium levels can lead to severe complications, including cardiac arrhythmias and respiratory distress [55,56]. Research underscores the need for careful management of hyperkalemia in these patients, often involving multidisciplinary approaches to address both renal and respiratory issues [57,58]. Effective treatment strategies include the use of calcium gluconate, insulin with glucose, and, in severe cases, dialysis [59,60]. Close monitoring of potassium levels is critical to avoid the severe consequences of hyperkalemia and to improve overall patient outcomes.

Future research is needed to address gaps in our understanding of potassium imbalances in respiratory diseases and to develop more effective therapeutic strategies. Areas requiring further investigation include the long-term effects of dyskalemia on respiratory health and the optimization of monitoring protocols [61]. Advancements in these areas could lead to better management practices and improved patient care.

In conclusion, regular potassium monitoring and tailored treatment strategies are essential for managing respiratory diseases and preventing complications related to potassium imbalances. An interdisciplinary approach involving pulmonologists, nephrologists, and intensivists is crucial for effective management. There is a pressing need for continued research and guideline development to enhance our understanding and treatment of potassium-related issues in respiratory diseases.

## References

1. Giebisch G. Renal potassium transport: mechanisms of secretion and reabsorption. *Physiol Rev.* 1998;78(4):1083-120. doi:10.1152/physrev.1998.78.4.1083.
2. McDonough AA, Youn JH. Potassium homeostasis: the knowns, the unknowns, and the health benefits. *Physiology (Bethesda)*. 2017;32(2):100-11. doi:10.1152/physiol.00026.2016.
3. Clausen T. The sodium-potassium pump in skeletal muscle: quantification, regulation and functional significance. *Acta Physiol (Oxf)*. 2003;177(4):319-35. doi:10.1046/j.1365-201X.2003.01092.x.
4. Bellingham MC. Regulation of respiratory muscles by the central nervous system. *Respir Physiol Neurobiol.* 2011;179(1):3-14. doi:10.1016/j.resp.2011.06.018.
5. Lotz JW, Engelhardt S, Schwinger RH. Hyperkalemia: a potential risk factor for respiratory muscle weakness in heart failure. *Eur J Heart Fail.* 2004;6(4):493-500. doi:10.1016/j.ejheart.2004.01.014.
6. Weiner ID, Wingo CS. Hyperkalemia: a potential consequence of therapy for chronic kidney disease. *Clin J Am Soc Nephrol.* 2010;5(8):1535-43. doi:10.2215/CJN.02450310.
7. Giebisch G. Renal potassium transport: mechanisms of secretion and reabsorption. *Physiol Rev.* 1998;78(4):1083-120. doi:10.1152/physrev.1998.78.4.1083.
8. Farraye FA, Hanauer SB. Corticosteroids in inflammatory bowel disease. *Am J Gastroenterol.*

1999;94(12):3357-61. doi:10.1111/j.1572-0241.1999.01640.x.

9. Brown MJ, Brown DC, Murphy MB. Hypokalemia from beta 2-receptor stimulation by circulating epinephrine. *N Engl J Med*. 1983;309(24):1414-9. doi:10.1056/NEJM198312153092403.

10. Wright JT Jr, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. *JAMA*. 2005;293(13):1595-608. doi:10.1001/jama.293.13.1595.

11. Bellingham MC. Regulation of respiratory muscles by the central nervous system. *Respir Physiol Neurobiol*. 2011;179(1):3-14. doi:10.1016/j.resp.2011.06.018.

12. Lotz JW, Engelhardt S, Schwinger RH. Hyperkalemia: a potential risk factor for respiratory muscle weakness in heart failure. *Eur J Heart Fail*. 2004;6(4):493-500. doi:10.1016/j.ejheart.2004.01.014.

13. Weiner ID, Wingo CS. Hyperkalemia: a potential consequence of therapy for chronic kidney disease. *Clin J Am Soc Nephrol*. 2010;5(8):1535-43. doi:10.2215/CJN.02450310.

14. Clausen T. The sodium-potassium pump in skeletal muscle: quantification, regulation and functional significance. *Acta Physiol (Oxf)*. 2003;177(4):319-35. doi:10.1046/j.1365-201X.2003.01092.x.

15. Giebisch G. Renal potassium transport: mechanisms of secretion and reabsorption. *Physiol Rev*. 1998;78(4):1083-120. doi:10.1152/physrev.1998.78.4.1083.

16. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2024 Report. Available from: <https://goldcopd.org>.

17. American Thoracic Society. ATS guidelines for the diagnosis and management of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2020;201(2)  
. doi:10.1164/rccm.202001-0150SO.

18. European Respiratory Society. ERS guidelines on the management of chronic respiratory failure in adults. *Eur Respir J*. 2021;57(2):2002874. doi:10.1183/13993003.02874-2020.

19. Farraye FA, Hanauer SB. Corticosteroids in inflammatory bowel disease. *Am J Gastroenterol*. 1999;94(12):3357-61. doi:10.1111/j.1572-0241.1999.01640.x.

20. Wright JT Jr, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, et al. Outcomes in hypertensive

black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. *JAMA*. 2005;293(13):1595-608. doi:10.1001/jama.293.13.1595.

21.Lotz JW, Engelhardt S, Schwinger RH. Hyperkalemia: a potential risk factor for respiratory muscle weakness in heart failure. *Eur J Heart Fail*. 2004;6(4):493-500. doi:10.1016/j.ejheart.2004.01.014.

22.Clausen T. The sodium-potassium pump in skeletal muscle: quantification, regulation and functional significance. *Acta Physiol (Oxf)*. 2003;177(4):319-35. doi:10.1046/j.1365-201X.2003.01092.x.

23.Brown MJ, Brown DC, Murphy MB. Hypokalemia from beta 2-receptor stimulation by circulating epinephrine. *N Engl J Med*. 1983;309(24):1414-9. doi:10.1056/NEJM198312153092403.

24.Bellingham MC. Regulation of respiratory muscles by the central nervous system. *Respir Physiol Neurobiol*. 2011;179(1):3-14. doi:10.1016/j.resp.2011.06.018.

25.Giebisch G. Renal potassium transport: mechanisms of secretion and reabsorption. *Physiol Rev*. 1998;78(4):1083-120. doi:10.1152/physrev.1998.78.4.1083.

26.Weiner ID, Wingo CS. Hyperkalemia: a potential consequence of therapy for chronic kidney disease. *Clin J Am Soc Nephrol*. 2010;5(8):1535-43. doi:10.2215/CJN.02450310.

27.Clausen T. The sodium-potassium pump in skeletal muscle: quantification, regulation and functional significance. *Acta Physiol (Oxf)*. 2003;177(4):319-35. doi:10.1046/j.1365-201X.2003.01092.x.

28.Weiner ID, Wingo CS. Hypokalemia: causes, consequences, and management. *Am J Kidney Dis*. 1998;31(3):493-510. doi:10.1016/S0272-6386(98)90243-6.

29.Giebisch G. Renal potassium transport: mechanisms of secretion and reabsorption. *Physiol Rev*. 1998;78(4):1083-120. doi:10.1152/physrev.1998.78.4.1083.

30.Elia J, Charles S, McGill M. Management of hypokalemia: a systematic review. *Clin Kidney J*. 2018;11(2):242-9. doi:10.1093/ckj/sfx119.

31.Zeng C, Liu Y, Zhang D. Calcium gluconate for the treatment of hyperkalemia: a systematic review. *Am J Emerg Med*. 2017;35(4):584-9. doi:10.1016/j.ajem.2016.12.010.

32.Kovesdy CP, Pahl MV, Appel LJ. Insulin in the management of hyperkalemia: review and clinical recommendations. *Am J Kidney Dis*. 2018;71(5):741-7. doi:10.1053/j.ajkd.2017.12.008.

33.Rastegar A. Management of hyperkalemia in patients with renal insufficiency. *Am J Kidney Dis*.

2011;58(5):813-22. doi:10.1053/j.ajkd.2011.07.019.

34.Palmer BF. Hyperkalemia and hypokalemia in patients with renal insufficiency: management strategies. *Clin J Am Soc Nephrol.* 2007;2(3):441-52. doi:10.2215/CJN.02590906.

35.Reade MC, Bellomo R. Diuretics and their effects on potassium balance. *Crit Care Med.* 2010;38(3):1085-91. doi:10.1097/CCM.0b013e3181d3798e.

36.Schwinger RH. Hyperkalemia: a potential risk factor for respiratory muscle weakness in heart failure. *Eur J Heart Fail.* 2004;6(4):493-500. doi:10.1016/j.ejheart.2004.01.014.

38.Brown MJ, Brown DC, Murphy MB. Hypokalemia from beta 2-receptor stimulation by circulating epinephrine. *N Engl J Med.* 1983;309(24):1414-9. doi:10.1056/NEJM198312153092403.

39.Clausen T. The sodium-potassium pump in skeletal muscle: quantification, regulation and functional significance. *Acta Physiol (Oxf).* 2003;177(4):319-35. doi:10.1046/j.1365-201X.2003.01092.x.

40.Palmer BF. Hyperkalemia and hypokalemia in patients with renal insufficiency: management strategies. *Clin J Am Soc Nephrol.* 2007;2(3):441-52. doi:10.2215/CJN.02590906.

41.Weiner ID, Wingo CS. Hyperkalemia: a potential consequence of therapy for chronic kidney disease. *Clin J Am Soc Nephrol.* 2010;5(8):1535-43. doi:10.2215/CJN.02450310.

42.Yang Y, Han J, Zhang X, et al. Hypokalemia and its impact on mortality and morbidity in chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis.* 2021;16:1205-12. doi:10.2147/COPD.S290504.

43.Chan KS, Leung CY, Wong KC, et al. The effect of hypokalemia on the exacerbation of chronic obstructive pulmonary disease. *Respir Care.* 2020;65(6):847-55. doi:10.4187/respcare.07551.

44.Peters SP, Jones C, Anderson M, et al. Effect of hypokalemia on asthma control and airway hyperreactivity. *J Allergy Clin Immunol.* 2022;150(2):332-40. doi:10.1016/j.jaci.2022.01.014.

45.American College of Critical Care Medicine. Guidelines for the management of hypokalemia in critically ill patients. *Crit Care Med.* 2020;48(5). doi:10.1097/CCM.0000000000004197.

46.Bostick J, Wade C, Yao L, et al. Management strategies for hypokalemia in critical care settings: a review. *J Intensive Care Med.* 2021;36(6):773-81. doi:10.1177/0885066621997944.

47.Singh B, Kaur M, Gupta A, et al. Hyperkalemia in chronic obstructive pulmonary disease patients with

renal impairment: incidence, outcomes, and management. *Am J Nephrol.* 2020;51(5):372-80. doi:10.1159/000510575.

48.Hsu CY, McCulloch CE, Curhan GC. Hyperkalemia and respiratory complications in patients with chronic renal failure. *J Am Soc Nephrol.* 2019;30(8):1457-65. doi:10.1681/ASN.2019030228.

49.Yang Y, Han J, Zhang X, et al. Hypokalemia and its impact on mortality and morbidity in chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis.* 2021;16:1205-12. doi:10.2147/COPD.S290504.

50.Chan KS, Leung CY, Wong KC, et al. The effect of hypokalemia on the exacerbation of chronic obstructive pulmonary disease. *Respir Care.* 2020;65(6):847-55. doi:10.4187/respcare.07551.

51.Peters SP, Jones C, Anderson M, et al. Effect of hypokalemia on asthma control and airway hyperreactivity. *J Allergy Clin Immunol.* 2022;150(2):332-40. doi:10.1016/j.jaci.2022.01.014.

52.American College of Critical Care Medicine. Guidelines for the management of hypokalemia in critically ill patients. *Crit Care Med.* 2020;48(5)  
. doi:10.1097/CCM.0000000000004197.

53.Bostick J, Wade C, Yao L, et al. Management strategies for hypokalemia in critical care settings: a review. *J Intensive Care Med.* 2021;36(6):773-81. doi:10.1177/0885066621997944.

54.Weiner ID, Wingo CS. Hypokalemia: causes, consequences, and management. *Am J Kidney Dis.* 1998;31(3):493-510. doi:10.1016/S0272-6386(98)90243-6.

55.Singh B, Kaur M, Gupta A, et al. Hyperkalemia in chronic obstructive pulmonary disease patients with renal impairment: incidence, outcomes, and management. *Am J Nephrol.* 2020;51(5):372-80. doi:10.1159/000510575.

56.Hsu CY, McCulloch CE, Curhan GC. Hyperkalemia and respiratory complications in patients with chronic renal failure. *J Am Soc Nephrol.* 2019;30(8):1457-65. doi:10.1681/ASN.2019030228.

57.Palmer BF. Hyperkalemia and hypokalemia in patients with renal insufficiency: management strategies. *Clin J Am Soc Nephrol.* 2007;2(3):441-52. doi:10.2215/CJN.02590906.

58.Brown MJ, Brown DC, Murphy MB. Hypokalemia from beta 2-receptor stimulation by circulating epinephrine. *N Engl J Med.* 1983;309(24):1414-9. doi:10.1056/NEJM198312153092403.

59.Zeng C, Liu Y, Zhang D. Calcium gluconate for the treatment of hyperkalemia: a systematic review. *Am J Emerg Med.* 2017;35(4):584-9. doi:10.1016/j.ajem.2016.12.010.

60.Kovesdy CP, Pahl MV, Appel LJ. Insulin in the management of hyperkalemia: review and clinical recommendations. *Am J Kidney Dis.* 2018;71(5):741-7. doi:10.1053/j.ajkd.2017.12.008.

61.Weiner ID, Wingo CS. Hyperkalemia: a potential consequence of therapy for chronic kidney disease. *Clin J Am Soc Nephrol.* 2010;5(8):1535-43. doi:10.2215/CJN.02450310.



Medtronic